Presenting characteristics, comorbidities, and outcomes among 390 patients hospitalized with COVID-19 pneumonia in a tertiary hospital

Abstract

Objectives: In this study, demographic characteristics, comorbidities, presenting symptoms, physical examination findings, laboratory findings, and administered drugs of the discharged or deceased patients admitted to our hospital and hospitalized with the COVID-19 diagnosis were compared to investigate the factors that affect mortality.

Methods: A retrospective study was performed and included COVID-19 pneumonia patients. 390 consecutive discharged or deceased patients, who were hospitalized in our hospital between March 20 and May 20, 2020, after detection of pneumonia and diagnosis of COVID-19, were included in the study.

Results: Of the 390 patients included in the study, 352 (90.25%) were discharged after recovery, while 38 (9.75%) were deceased. The average age of all the patients was 49.46 ± 17.86 years, the average age of the discharged patients was 47.19 ± 16.76 years, and the average age of the deceased patients was 70.42 ± 13.7 years. The average age of deceased patients was significantly higher. Of all the patients, 40.8% was PCR positive.

Conclusions: The present study revealed that the drugs that patients take due to their comorbidities have no effect on the prognosis of the disease and that the presence of comorbidity itself is indicative of the poor prognosis. Taking into account the PCR positivity of 57.9%, even in deceased patients, we believe PCR is inadequate in the diagnosis, and CT is much more valuable in this regard.

Keywords

• COVID-19 disease
• CT images
• Pneumonia
• Reverse transcription polymerase chain reaction

References

1. 1. World Health Organization. Coronavirus Disease (COVID-19) Situation Report − 170. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200708-covid-19-sitrep-170.pdf?sfvrsn=bca86036_2. Accessed in 2020 (Aug 28).
2. 2. Liu J, Zheng X, Tong Q, Li W, Wang B, Sutter K, et al. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. J Med Virol 2020;92:491-4.
3. 3. Selçuk M, Çınar T, Keskin M, Çiçek V, Kılıç Ş, Kenan B, et al. Is the use of ACE inb/ARBs associated with higher in-hospital mortality in Covid-19 pneumonia patients? Clin Exp Hypertens 2020;42:738-42.
4. 4. Bravi F, Flacco ME, Carradori T, Volta CA, Cosenza G, De Togni A, et al. Predictors of severe or lethal COVID-19, including angiotensin converting enzyme inhibitors and angiotensin II receptor blockers, in a sample of infected Italian citizens. PLoS One 2020;15:e0235248.
5. 5. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054-62.
6. 6. Istituto Superiore di Sanità. Dati della Sorveglianza integrata COVID-19 in Italia [COVID-19 integrated surveillance data in Italy]. Available from: https://www.epicentro.iss.it/coronavirus/sars-cov-2-dashboard. Accessed in 2020 (Aug 28).
7. 7. T.C Sağlık Bakanlığı Korona Tablosu. Available from: https://covid19.saglik.gov.tr/. Accessed in 2020 (Aug 28).
8. 8. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA 2020;323:2052-9.

9. 9. Guan WJ, Ni ZY, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708-20.
10. 10. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 2020;8:e21.
11. 11. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507-13.
12. 12. Liu Y, Du X, Chen J, Jin Y, Peng L, Wang HHX, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J Infect 2020;81:e6-e12.
13. 13. Liabeuf S, Moragny J, Bennis Y, Batteux B, Brochot E, Schmit JL, et al. Association between renin-angiotensin system inhibitors and COVID-19 complications. Eur Heart J Cardiovasc Pharmacother 2020 Jun 12;pvaa062. doi: 10.1093/ehjcvp/pvaa062.
14. 14. Sommerstein R, Kochen MM, Messerli FH, Gräni C. Coronavirus disease 2019 (COVID-19): do angiotensin-converting enzyme inhibitors/angiotensin receptor blockers have a biphasic effect? J Am Heart Assoc 2020;9:e016509.
15. 15. Rico-Mesa JS, White A, Anderson AS. Outcomes in patients with COVID-19 infection taking ACEI/ARB. Curr Cardiol Rep 2020;22:1-4.
16. 16. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med 2020;382:e102.
17. 17. Pranata R, Permana H, Huang I, Lim MA, Soetedjo NNM, Supriyadi R, et al. The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Diabetes Metab Syndr 2020;14:983-90.
18. 18. Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician. American Heart Association. Available from: https://newsroom.heart.org/news/patients-taking-ace-i-and-arbs-who-contract-covid-19-should-continue-treatment-unless-otherwise-advised-by-their-physician. Accessed in 2020 (Aug 28).
19. 19. Mahdjoub E, Mohammad W, Lefevre T, Debray MP, Khalil A. Admission chest CT score predicts 5-day outcome in patients with COVID-19. Intensive Care Med 2020;46:1648-50.
20. 20. Yuan M, Yin W, Tao Z, Tan W, Hu Y. Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China. PLoS One 2020;15:1-10.
21. 21. Hu L, Chen S, Fu Y, Gao Z, Long H, Ren HW, et al. Risk factors associated with clinical outcomes in 323 COVID-19 hospitalized patients in Wuhan, China. Clin Infect Dis 2020;71:2089-98.